Plasma markers of COVID-19 severity: a pilot study
Abstract Background SARS-CoV-2 infected patients show heterogeneous clinical presentations ranging from mild symptoms to severe respiratory failure and death. Consequently, various markers reflect this wide spectrum of disease presentations. Methods Our pilot cohort included moderate (n = 10) and se...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-022-02272-7 |
| _version_ | 1828265313031946240 |
|---|---|
| author | Julia Beimdiek Sabina Janciauskiene Sabine Wrenger Sonja Volland Adriana Rozy Jan Fuge Beata Olejnicka Isabell Pink Thomas Illig Alexander Popov Joanna Chorostowska Falk F. R. Buettner Tobias Welte |
| author_facet | Julia Beimdiek Sabina Janciauskiene Sabine Wrenger Sonja Volland Adriana Rozy Jan Fuge Beata Olejnicka Isabell Pink Thomas Illig Alexander Popov Joanna Chorostowska Falk F. R. Buettner Tobias Welte |
| author_sort | Julia Beimdiek |
| collection | DOAJ |
| description | Abstract Background SARS-CoV-2 infected patients show heterogeneous clinical presentations ranging from mild symptoms to severe respiratory failure and death. Consequently, various markers reflect this wide spectrum of disease presentations. Methods Our pilot cohort included moderate (n = 10) and severe (n = 10) COVID-19 patients, and 10 healthy controls. We determined plasma levels of nine acute phase proteins (APPs) by nephelometry, and full-length (M65), caspase-cleaved (M30) cytokeratin 18, and ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 motif 13) by ELISA. In addition, we examined whole plasma N-glycosylation by capillary gel electrophoresis coupled to laser-induced fluorescence detection (CGE-LIF). Results When compared to controls, COVID-19 patients had significantly lower concentrations of ADAMTS13 and albumin (ALB) but higher M30, M65, α1-acid glycoprotein (AGP), α1-antitrypsin (AAT), ceruloplasmin (CP), haptoglobin (HP), and high-sensitivity C-reactive protein (hs-CRP). The concentrations of α1-antichymotrypsin (ACT), α2-macroglobulin (A2MG) and serum amyloid A (SAA) proteins did not differ. We found significantly higher levels of AAT and M65 but lower ALB in severe compared to moderate COVID-19 patients. N-glycan analysis of the serum proteome revealed increased levels of oligomannose- and sialylated di-antennary glycans and decreased non-sialylated di-antennary glycan A2G2 in COVID-19 patients compared to controls. Conclusions COVID-19-associated changes in levels and N-glycosylation of specific plasma proteins highlight complexity of inflammatory process and grant further investigations. |
| first_indexed | 2024-04-13T04:37:30Z |
| format | Article |
| id | doaj.art-15e691f1a242452fa7cc0b2bc025ec12 |
| institution | Directory Open Access Journal |
| issn | 1465-993X |
| language | English |
| last_indexed | 2024-04-13T04:37:30Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-15e691f1a242452fa7cc0b2bc025ec122022-12-22T03:02:07ZengBMCRespiratory Research1465-993X2022-12-0123111110.1186/s12931-022-02272-7Plasma markers of COVID-19 severity: a pilot studyJulia Beimdiek0Sabina Janciauskiene1Sabine Wrenger2Sonja Volland3Adriana Rozy4Jan Fuge5Beata Olejnicka6Isabell Pink7Thomas Illig8Alexander Popov9Joanna Chorostowska10Falk F. R. Buettner11Tobias Welte12Institute of Clinical Biochemistry, Hannover Medical SchoolDepartment of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL) Hannover University SchoolDepartment of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL) Hannover University SchoolHannover Unified Biobank, Hannover Medical SchoolDepartment of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung DiseasesDepartment of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL) Hannover University SchoolDepartment of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL) Hannover University SchoolDepartment of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL) Hannover University SchoolHannover Unified Biobank, Hannover Medical SchoolHannover Unified Biobank, Hannover Medical SchoolDepartment of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung DiseasesInstitute of Clinical Biochemistry, Hannover Medical SchoolDepartment of Pulmonary and Infectious Diseases, Hannover Medical School, BREATH German Center for Lung Research (DZL) Hannover University SchoolAbstract Background SARS-CoV-2 infected patients show heterogeneous clinical presentations ranging from mild symptoms to severe respiratory failure and death. Consequently, various markers reflect this wide spectrum of disease presentations. Methods Our pilot cohort included moderate (n = 10) and severe (n = 10) COVID-19 patients, and 10 healthy controls. We determined plasma levels of nine acute phase proteins (APPs) by nephelometry, and full-length (M65), caspase-cleaved (M30) cytokeratin 18, and ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type-1 motif 13) by ELISA. In addition, we examined whole plasma N-glycosylation by capillary gel electrophoresis coupled to laser-induced fluorescence detection (CGE-LIF). Results When compared to controls, COVID-19 patients had significantly lower concentrations of ADAMTS13 and albumin (ALB) but higher M30, M65, α1-acid glycoprotein (AGP), α1-antitrypsin (AAT), ceruloplasmin (CP), haptoglobin (HP), and high-sensitivity C-reactive protein (hs-CRP). The concentrations of α1-antichymotrypsin (ACT), α2-macroglobulin (A2MG) and serum amyloid A (SAA) proteins did not differ. We found significantly higher levels of AAT and M65 but lower ALB in severe compared to moderate COVID-19 patients. N-glycan analysis of the serum proteome revealed increased levels of oligomannose- and sialylated di-antennary glycans and decreased non-sialylated di-antennary glycan A2G2 in COVID-19 patients compared to controls. Conclusions COVID-19-associated changes in levels and N-glycosylation of specific plasma proteins highlight complexity of inflammatory process and grant further investigations.https://doi.org/10.1186/s12931-022-02272-7COVID-9 severityAcute phase proteinsCell deathInflammationN-glycosylationTrombosis |
| spellingShingle | Julia Beimdiek Sabina Janciauskiene Sabine Wrenger Sonja Volland Adriana Rozy Jan Fuge Beata Olejnicka Isabell Pink Thomas Illig Alexander Popov Joanna Chorostowska Falk F. R. Buettner Tobias Welte Plasma markers of COVID-19 severity: a pilot study Respiratory Research COVID-9 severity Acute phase proteins Cell death Inflammation N-glycosylation Trombosis |
| title | Plasma markers of COVID-19 severity: a pilot study |
| title_full | Plasma markers of COVID-19 severity: a pilot study |
| title_fullStr | Plasma markers of COVID-19 severity: a pilot study |
| title_full_unstemmed | Plasma markers of COVID-19 severity: a pilot study |
| title_short | Plasma markers of COVID-19 severity: a pilot study |
| title_sort | plasma markers of covid 19 severity a pilot study |
| topic | COVID-9 severity Acute phase proteins Cell death Inflammation N-glycosylation Trombosis |
| url | https://doi.org/10.1186/s12931-022-02272-7 |
| work_keys_str_mv | AT juliabeimdiek plasmamarkersofcovid19severityapilotstudy AT sabinajanciauskiene plasmamarkersofcovid19severityapilotstudy AT sabinewrenger plasmamarkersofcovid19severityapilotstudy AT sonjavolland plasmamarkersofcovid19severityapilotstudy AT adrianarozy plasmamarkersofcovid19severityapilotstudy AT janfuge plasmamarkersofcovid19severityapilotstudy AT beataolejnicka plasmamarkersofcovid19severityapilotstudy AT isabellpink plasmamarkersofcovid19severityapilotstudy AT thomasillig plasmamarkersofcovid19severityapilotstudy AT alexanderpopov plasmamarkersofcovid19severityapilotstudy AT joannachorostowska plasmamarkersofcovid19severityapilotstudy AT falkfrbuettner plasmamarkersofcovid19severityapilotstudy AT tobiaswelte plasmamarkersofcovid19severityapilotstudy |